ClinicalTrials.gg
RecruitingNCT06451172ASOTARIUpdated Jun 11, 2024

Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis

An Early Phase 1 interventional study of ASO in Bacterial Keratitis, Antibiotic-resistant Bacteria and Infections, Bacterial, sponsored by Eye & ENT Hospital of Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-11.

Sponsored by Eye & ENT Hospital of Fudan University · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Registered 7 months after the study started (first participant enrolled Oct 2023, registered May 2024).
  • Started Oct 2023; still recruiting 3 years 1 month later.
Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and efficacy of GP-asPNA for in vivo treatment of severe antibiotic resistant bacterial keratitis.

Read the detailed description

This is a study of antisense oligonucleotides (ASOs) in adult (ages 18 to 70) participants with severe antibiotic resistant bacterial keratitis. Approximately 20 participants will be enrolled.

Infectious keratitis or endophthalmitis, mainly caused by the trauma or intraocular surgical operation, has posed a grave threat to human vision health. Among them, infectious keratitis is the most common blinding keratopathy in developing countries. We develop a novel kind of Trojan strategy to specifically deliver ASOs into diverse bacteria rather than mammalian cells through the bacterial-specific ATP-binding cassette (ABC) sugar transporter. Compared with their cell-penetrating peptide counterparts, the antisense peptide nucleic acid modified with glucose polymer can be selectively internalized into human-derived multidrug- resistant Escherichia coli and methicillin-resistant Staphylococcus aureus, and they display a much higher uptake rate.

The follow-up period was 90 days, and the patients will be followed up 1 days, 3±1 days, 7±1 days, 14±2 days, 30±2 days, and 90±5 days after treatment.

02

Conditions studied

  • Bacterial Keratitis
  • Antibiotic-resistant Bacteria
  • Infections, Bacterial
  • Corneal Diseases
  • Eye Diseases
  • Vision Disorders
  • Sensation Disorders
  • Blindness
  • Antisense Peptide Nucleic Acid
  • Antibacterial Therapy

Keywords

  • Bacterial Keratitis
  • Infections, Bacterial
  • Corneal Diseases
  • Eye Diseases
03

In context

Bacterial Infections

584 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

This study's planned enrollment of 20 is below the median of 84 across 382 interventional studies indexed under Bacterial Infections.

Browse Bacterial Infections studies →

Lead sponsor

Eye & ENT Hospital of Fudan University is the lead sponsor of 126 studies on the registry; 70 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The results of antimicrobial susceptibility testing in patients with bacterial keratitis showed multidrug-resistant bacterial infections, and the existing commercial antibiotics could not effectively control the disease.
  • Age over 18 years.
  • No systemic immune eye disease.
  • Good eyelid structure and blink function.
  • Exists the potential of visual recovery by evaluation of ocular structure and function.
  • Subjects or their legal guardians voluntarily participate in this study, sign , good compliance and cooperation with follow-up visits.

Exclusion criteria

Exclusion Criteria:

  • Lacrimal coating and blink function loss.
  • Schirmer's test result is less than 2mm for severe dry eye disease.
  • Pregnant and lactating women (pregnancy defined in this study as positive urine pregnancy test).
  • Currently is involved in clinical trials of other drugs or medical devices.
  • Active eye infection (including but not limited to: blepharitis, infectious conjunctivitis, sclerotitis, endophthalmitis) in target eye or contralateral eye within 30 days prior to enrollment.
  • Ocular surface malignant tumor.
  • A history of allergic reaction or allergy to sodium luciferin, allergy to protein products used for treatment or diagnosis, allergy to ≥ 2 drugs or non-drug factors, or current allergic disease.
  • current in an infectious disease requiring oral, intramuscular or intravenous administration.
  • Patients with systemic immune diseases.
  • Any uncontrolled clinical problems (such as severe mental, neurological, cardiovascular, respiratory and other systemic diseases and malignant neoplasms).
  • Not effective .
  • In uncontrolled hypertension, systolic is no less than 160 mmhg, diastolic is no less than 100 mmhg.
  • In uncontrolled diabetes, fasting glucose is no less than 10.0umol/L.
  • Renal insufficiency, serum creatinine is more than 133umol/L.
  • Arrhythmia, myocardial ischemia, myocardial infarction (diagnosed by ).
  • Liver dysfunction, al ANINE aminotransferase and levels are higher than 80 IU/L.
  • level is below 100,000 /uL or above 450,000 /uL.
  • level is below 10.0g/dL (male) or 9.0g/dL (female).
  • No anticoagulant was used, is higher than 16s, and thrombin time of activated part is higher than 50s.
  • infection (HIV-positive).
  • Subjects lack compliance with the study or the ability to sign .
  • There are currently signs of systemic infection, including fever and ongoing antibiotic treatment (in this study, systemic infection was defined as deviation from normal values of white blood cells, lymphocytes, and neutrophils on routine blood tests).
  • Administration of and other systemic drugs.
  • The investigator judges other conditions unsuitable for the trial
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    ASO Single Group

    ASO eye drops are used through the local administration. Dosage form: eye drop solution. Dose:20uL. Frequency of administration: 3 times per day.

    Drug: ASO

Interventions

  • DrugASO

    Anticipated 20 Participants will receive a single group administered via eye drops in the study eye.

06

What researchers measure

Primary outcomes

  1. Bacteria testing outcome of the intervention eye

    Assess the efficacy of bacteria clearance based on RNA sequencing data using techniques such as ELISA and PCR. For instance, real-time polymerase chain reaction (PCR) is utilized to identify 16S rRNA in corneal biopsy samples.

    Time frame: 90 Days

  2. Ophthalmic therapeutic effect of ASO eye drops

    Measure the decrease in size, depth and infiltrate of the ulcer in millimeters by slit lamp biomicroscopy.

    Time frame: 90 Days

Secondary outcomes

  1. Visual improvement compared with baseline

    Judge the visual recovery progress according to visual examination results on day 1,3±1,7±1,14±2,30±2,90±5.

    Time frame: 90 Days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Austin A, Lietman T, Rose-Nussbaumer J. Update on the Management of Infectious Keratitis. Ophthalmology. 2017 Nov;124(11):1678-1689. doi: 10.1016/j.ophtha.2017.05.012. Epub 2017 Sep 21. PubMed 28942073 ↗
  • Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. Nature. 2016 Jan 21;529(7586):336-43. doi: 10.1038/nature17042. PubMed 26791724 ↗
  • Liu M, Chu B, Sun R, Ding J, Ye H, Yang Y, Wu Y, Shi H, Song B, He Y, Wang H, Hong J. Antisense Oligonucleotides Selectively Enter Human-Derived Antibiotic-Resistant Bacteria through Bacterial-Specific ATP-Binding Cassette Sugar Transporter. Adv Mater. 2023 Jul;35(28):e2300477. doi: 10.1002/adma.202300477. Epub 2023 May 26. PubMed 37002615 ↗
  • Zhang Q, Song B, Xu Y, Yang Y, Ji J, Cao W, Lu J, Ding J, Cao H, Chu B, Hong J, Wang H, He Y. In vivo bioluminescence imaging of natural bacteria within deep tissues via ATP-binding cassette sugar transporter. Nat Commun. 2023 Apr 22;14(1):2331. doi: 10.1038/s41467-023-37827-9. PubMed 37087540 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Oct 2024, 11 months after the start.

Of 67 phase 1 interventional studies under Bacterial Infections, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's planned 11 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2024
First posted
Jun 11, 2024
StartActual
Oct 11, 2023
Primary completionEst.
Oct 1, 2024
CompletionEst.
Oct 31, 2026
Last update
Jun 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06451172
Collaborators
Soochow University
Responsible party
Sponsor
First posted
Jun 11, 2024
Start date
Oct 11, 2023
Primary completion
Oct 1, 2024 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Jun 11, 2024

Study contacts

Jiaxu Hong, M.D., Ph.D
Contact
chengmingruicmr@163.com
+86-021-64377134
Jiaxu Hong, M.D., Ph.D
study director · Eye, and ENT Hospital,Shanghai Medical College, Fudan University,Shanghai, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion